Submitted by dcc on Thu, 2017-02-16 13:44 Study Title: A Phase 1 Study of Selinexor (KPT-330; IND #125052); A Selective XPO1 Inhibitor; In Recurrent and Refractory Pediatric Solid Tumors; Including CNS TumorsCIRB: Pediatric CIRBLead Group: COGStatus: ActiveReview Status: Available to Open
